To promote the new diabetes drug Byetta (aka Exenatide injection), Eli Lilly & Co. and partner Amylin Pharmaceuticals are featuring this guy, the Gila monster, during TV interviews today with Gilamonster_1the drug's discoverer and a diabetes doctor. The drug is of course the one derived from the saliva of this venomous lizard.

Byetta seems to have exciting possiblities to increase insulin secretion in Type 2 diabetics, but once again, you will find most press coverage in the Finance Section of the newspaper: Business Week says Eli Lilly's "flowering of new diabetes drugs" will put it ahead of the competition.

Furthermore, the company is expected to "raise its profile in the diabetes arena" this coming weekend at the American Diabetes Association's annual scientific sessions in San Diego, CA. That's the big annual conference, expected to attract more than 13,500 researchers and doctors this year!

And guess who will be there? Yup, this little 'ol diabetes blogger personally. The whole thing happened so fast, I've hardly got time to pack my test strips. But I'm off to San Diego tomorrow to see what I shall see.

Lilly certainly won't be the only company in the spotlight: its partner Amylin will be making at least 12 presentations on its new drugs for improving BG control. More on all that this weekend...

News nuggets from around the diabetes community

NEWSFLASH: FDA Clears Dexcom Share Direct
Dexcom gets regulatory approval of its 'on-the-go' mobile apps for CGM data-sharing.
State of the Union: It's Time to Cure Diabetes
President launching new precision medicine initiative to better treat, cure diseases like diabetes.
'Robotic Pancreas' Appears On American Idol
Carlos Santana's nephew Adam Lasher shows off Dexcom G4 during live performance.

closing banner
Disclaimer: Content created by the Diabetes Mine team. For more details click here.

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.